サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793756

肺線維症治療の世界市場

Pulmonary Fibrosis Treatment

出版日
ページ情報
英文 376 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.34円
肺線維症治療の世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 376 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肺線維症治療の世界市場は2030年までに42億米ドルに達する見込み

2024年に32億米ドルと推定される肺線維症治療の世界市場は、2024～2030年の分析期間にCAGR 5.0％で成長し、2030年には42億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである単剤療法は、CAGR 5.6%を記録し、分析期間終了時には27億米ドルに達すると予測されます。併用療法セグメントの成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は8億5,970万米ドルと推定、中国はCAGR 9.1％で成長予測

米国の肺線維症治療市場は、2024年に8億5,970万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億9,480万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.0％と3.9％と予測されています。欧州では、ドイツがCAGR 3.0%で成長すると予測されています。

世界の肺線維症治療市場- 主要動向と促進要因まとめ

肺線維症が呼吸器治療薬の高優先ターゲットに浮上しつつあるのはなぜか？

肺線維症、特に特発性肺線維症（IPF）は、その進行性で不可逆的な性質と長期予後の悪さから、医薬品開発企業やヘルスケアシステムからの注目度が高まっています。この疾患は肺組織の瘢痕化を特徴とし、肺機能、運動能力、ひいては生存率の着実な低下をもたらします。IPFの生存期間中央値は診断後3～5年であり、治療法の革新は歴史的に限られていました。しかし、診断意識の向上、先進的な画像診断、バイオマーカーを用いた層別化により、より早期の介入が可能となり、治療可能な患者層が拡大しています。

IPFやその他の線維性間質性肺疾患（ILDs）の世界の負担は、高齢化、環境曝露、関節リウマチや全身性硬化症などの併存疾患のために増加しています。線維化メカニズムの理解が進むにつれて、抗線維化療法は肺機能低下を遅らせるために疾患経過の早期から開始すべきであるというコンセンサスが高まっています。このため、米国胸部学会（ATS）などの組織によるガイドラインが発展し、日常的な肺機能モニタリングと治療薬への早期アクセスを提唱しています。その結果、治療法は対症療法から疾患修飾療法へと移行しつつあります。

市場開拓を形成している薬剤クラス別、新規メカニズム、患者層は？

現在の治療の主流は、ピルフェニドン（エスブリエット）とニンテダニブ（オフェブ）の2つの抗線維化薬です。両剤は米国、EU、アジア太平洋地域でIPF治療薬として承認されており、強制生命維持能力（FVC）の低下を遅らせる効果が実証されています。ピルフェニドンは経口ピリドン系化合物で、TGF-βをはじめとする線維化サイトカインを阻害することにより、抗炎症作用と抗線維化作用を発揮します。チロシンキナーゼ阻害剤であるニンテダニブは、PDGF、FGF、VEGFなどの経路を標的とします。両薬剤とも消化器系の副作用を伴い、長期にわたるコンプライアンスが必要であるが、ほとんどの高所得国では依然として標準治療となっています。

ニンテダニブはIPFにとどまらず、進行性線維性ILDや全身性硬化症関連ILDにも適応を拡大しています。これは、複数の線維化病態に対する抗線維化薬の位置づけを変更する、より広範な傾向を反映しています。現在、臨床試験では、抗線維化薬と免疫調節薬、抗サイトカイン療法、抗老化薬などの併用療法が試験されています。PLN-74809（Pliant Therapeuticsによるデュアルインテグリン阻害薬）やPRM-151（ziltivekimab）などの標的分子は、線維芽細胞の活性化とECMリモデリングを阻害する目的で開発中です。小児線維性肺疾患やCOVID後の肺線維症などの希少患者コホートも、パイプラインの多様化戦略において注目を集めています。

診断、デジタルツール、臨床ガイドラインは、治療の普及と最適化にどのような影響を与えているか？

高解像度コンピューター断層撮影（HRCT）、肺生検技術、デジタル聴診ツールの改善により、診断精度が向上し、線維症のサブタイプの層別化が可能になっています。過敏性肺炎や非特異的間質性肺炎などの他のILDとIPFを区別する能力は、治療の違いを考慮すると非常に重要です。HRCT上の通常の間質性肺炎（UIP）のようなパターンを診断するための補助として、AIを活用した画像解析や機械学習ツールが登場しており、治療適格性や試験募集に情報を提供することができます。

遠隔医療プラットフォームとデジタル吸入アドヒアランスツールは、特に遠隔地や十分なサービスを受けていない地域の患者を対象に、慢性疾患管理を支援しています。患者報告アウトカム測定（PROM）やモバイルスパイロメトリーは、縦断的モニタリングの枠組みにますます統合されつつあり、臨床医が患者の機能性や進行速度に基づいて治療レジメンを調整できるようになっています。ATS、ERS、NICEなどの組織によるガイドラインでは、現在、集学的ディスカッション（MDD）と3～6カ月ごとの定期的な機能評価が重視されており、治療調整や適時のエスカレーションが容易になっています。

世界の肺線維症治療市場の成長を促進する要因は？

世界の肺線維症治療市場の成長は、疾患有病率の上昇、抗線維化療法の適応拡大、複数の線維性ILDサブタイプにまたがる強固なパイプライン革新が牽引しています。さらに、米国、EU、日本におけるアンメット・クリニカル・ニーズの高さ、希少疾病用医薬品（オーファンドラッグ）優遇措置、薬事規制の迅速化によって、製薬企業の関心が高まっています。ヘルスケアシステムが呼吸器内科ネットワークを通じて早期発見に習熟するにつれて、診断・治療対象は大幅に拡大すると予想されます。

さらに、バイオテクノロジー企業と大手製薬企業との戦略的提携、ライセンシング契約、買収により、臨床開発の迅速化が進んでいます。実臨床でのエビデンスが市場参入や価格戦略に組み込まれる傾向が強まっており、新興市場でも高コストの抗線維化薬がより広く償還されるようになっています。地域的には、北米と西欧が診断と治療法の普及で引き続きリードしているが、アジア太平洋市場は認知度の向上と償還政策の進化により急成長しています。

主な市場参入企業には、ロシュ、ベーリンガーインゲルハイム、ファイブロジェン、プライアント・セラピューティクス、ガラパゴスNV、ベレロフォン・セラピューティクス、ユナイテッド・セラピューティクスなどがあります。次世代線維症治療薬やコンパニオン診断薬の登場が予想されることから、同市場は精密治療、早期治療開始、全人的な患者ケアモデルを中心に長期的な成長が見込まれています。

セグメント

治療タイプ（単剤療法、併用療法、対症療法）、適応症（特発性肺線維症、家族性PF、その他の適応症）、流通チャネル（病院薬局、小売薬局、通販薬局流通チャネル）

調査対象企業の例

  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • FibroGen, Inc.
  • Galapagos NV
  • Genentech（Roche）
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • MediciNova, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pliant Therapeutics Inc.
  • Promedior, Inc.
  • Roche Holding AG
  • United Therapeutics Corporation
  • Vicore Pharma AB

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37846

Global Pulmonary Fibrosis Treatment Market to Reach US$4.2 Billion by 2030

The global market for Pulmonary Fibrosis Treatment estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.2 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Monotherapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Combination Therapy segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$859.7 Million While China is Forecast to Grow at 9.1% CAGR

The Pulmonary Fibrosis Treatment market in the U.S. is estimated at US$859.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$894.8 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Pulmonary Fibrosis Treatment Market - Key Trends & Drivers Summarized

Why Is Pulmonary Fibrosis Emerging as a High-Priority Target in Respiratory Therapeutics?

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), has drawn increasing focus from pharmaceutical developers and healthcare systems due to its progressive, irreversible nature and poor long-term prognosis. The disease is characterized by scarring of lung tissues, leading to a steady decline in lung function, exercise capacity, and ultimately survival. IPF has a median survival time of three to five years post-diagnosis, and therapeutic innovation has been historically limited. However, rising diagnostic awareness, advanced imaging modalities, and biomarker-led stratification are facilitating earlier intervention and expanding the treatment-eligible patient pool.

The global burden of IPF and other fibrotic interstitial lung diseases (ILDs) is increasing due to aging populations, environmental exposures, and comorbid conditions such as rheumatoid arthritis and systemic sclerosis. As understanding of fibrotic mechanisms improves, there is a growing consensus that antifibrotic therapies should be initiated earlier in the disease course to decelerate lung function loss. This has led to evolving guidelines by organizations such as the American Thoracic Society (ATS), advocating for routine pulmonary function monitoring and earlier access to therapeutic agents. As a result, the therapeutic landscape is transitioning from symptom management to disease-modifying interventions.

Which Drug Classes, Novel Mechanisms, and Patient Segments Are Shaping Market Development?

The current treatment landscape is dominated by two antifibrotic agents: pirfenidone (Esbriet) and nintedanib (Ofev). Both drugs received approval in the U.S., EU, and Asia-Pacific for IPF management and have demonstrated efficacy in slowing forced vital capacity (FVC) decline. Pirfenidone, an oral pyridone compound, exerts anti-inflammatory and antifibrotic effects by inhibiting TGF-β and other fibrogenic cytokines. Nintedanib, a tyrosine kinase inhibitor, targets pathways including PDGF, FGF, and VEGF. Both agents are associated with gastrointestinal side effects and require long-term compliance, yet remain the standard of care in most high-income countries.

Beyond IPF, nintedanib has gained expanded indication for progressive fibrosing ILDs and systemic sclerosis-associated ILD. This reflects a broader trend in repositioning antifibrotics for multiple fibrotic pathologies. Clinical trials are now testing combination regimens, including the pairing of antifibrotics with immunomodulators, anti-cytokine therapies, and senolytic agents. Targeted molecules such as PLN-74809 (a dual integrin inhibitor by Pliant Therapeutics) and PRM-151 (ziltivekimab) are under development with the aim to interrupt fibroblast activation and ECM remodeling. Rare patient cohorts, such as pediatric fibrotic lung disease and post-COVID pulmonary fibrosis, are also gaining attention in pipeline diversification strategies.

How Are Diagnostics, Digital Tools, and Clinical Guidelines Impacting Treatment Uptake and Optimization?

Improved high-resolution computed tomography (HRCT), lung biopsy techniques, and digital auscultation tools are enhancing diagnostic accuracy and enabling stratification of fibrosis subtypes. The ability to distinguish IPF from other ILDs-such as hypersensitivity pneumonitis and nonspecific interstitial pneumonia-is critical, given treatment differences. AI-powered imaging analysis and machine learning tools are emerging as aids in diagnosing patterns such as usual interstitial pneumonia (UIP) on HRCT, which can inform treatment eligibility and trial recruitment.

Telehealth platforms and digital inhaler adherence tools are supporting chronic disease management, especially for patients in remote or underserved areas. Patient-reported outcome measures (PROMs) and mobile spirometry are increasingly integrated into longitudinal monitoring frameworks, allowing clinicians to tailor treatment regimens based on patient functionality and progression speed. Guidelines from organizations such as ATS, ERS, and NICE now emphasize multidisciplinary discussions (MDDs) and routine functional assessment every 3-6 months, facilitating treatment adjustment and timely escalation.

What Factors Are Driving the Growth of the Global Pulmonary Fibrosis Treatment Market?

The growth in the global pulmonary fibrosis treatment market is driven by rising disease prevalence, expanding indications for antifibrotic therapies, and robust pipeline innovation across multiple fibrotic ILD subtypes. Pharmaceutical interest is further fueled by high unmet clinical needs, orphan drug incentives, and accelerated regulatory pathways in the U.S., EU, and Japan. As healthcare systems become more adept at early detection through pulmonology networks, the diagnosed and treated population base is expected to expand significantly.

Furthermore, strategic collaborations, licensing deals, and acquisitions between biotechs and large pharma players are facilitating faster clinical development. Real-world evidence is increasingly being incorporated into market access and pricing strategies, enabling broader reimbursement of high-cost antifibrotics in emerging markets. Geographically, North America and Western Europe continue to lead in terms of diagnosis and therapy adoption, but Asia-Pacific markets are seeing rapid growth due to increasing awareness and evolving reimbursement policies.

Major market participants include Roche, Boehringer Ingelheim, FibroGen, Pliant Therapeutics, Galapagos NV, Bellerophon Therapeutics, and United Therapeutics. With the anticipated arrival of next-generation fibrosis inhibitors and companion diagnostics, the market is poised for long-term growth centered on precision therapy, earlier treatment initiation, and holistic patient care models.

SCOPE OF STUDY:

The report analyzes the Pulmonary Fibrosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Monotherapy, Combination Therapy, Symptomatic Treatment); Indication (Idiopathic Pulmonary Fibrosis, Familial PF, Other Indications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacy Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • FibroGen, Inc.
  • Galapagos NV
  • Genentech (Roche)
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • MediciNova, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pliant Therapeutics Inc.
  • Promedior, Inc.
  • Roche Holding AG
  • United Therapeutics Corporation
  • Vicore Pharma AB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Pulmonary Fibrosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Idiopathic Pulmonary Fibrosis Drives Demand for Targeted Therapeutics
    • Advancements in Antifibrotic Drug Development Strengthen Business Case for New Entrants
    • Increased Clinical Research in Combination Therapies Expands Treatment Possibilities
    • Growth in Aging Population Throws the Spotlight on Fibrosis-Related Lung Disorders
    • Focus on Biomarker-Based Diagnosis Enhances Early Intervention Strategies
    • Expansion of Patient Access Programs in Emerging Markets Accelerates Drug Penetration
    • Regulatory Fast-Track Designations Propel Market Entry of Novel Therapeutics
    • Collaborations With Academic Institutions Foster Innovation in Pathogenesis Research
    • Rising Use of AI in Clinical Trials Enhances Drug Development Efficiency
    • Investment in Inhaled Therapy Delivery Systems Improves Patient Compliance
    • Increased Awareness Campaigns Drive Earlier Diagnosis and Therapeutic Uptake
    • Use of Digital Health Platforms Supports Monitoring of Long-Term Fibrosis Progression
    • Emergence of Precision Medicine Approaches Expands Addressable Patient Subsets
    • Integration of Genomic Insights Into Treatment Pathways Strengthens Personalization
    • Rising Focus on Rare Disease Therapeutics Promotes Investment in Fibrosis Pipelines
    • Government Incentives for Orphan Drug Development Strengthen R&D Funding Support
    • Entry Into Biosimilars and Generics Intensifies Market Competition
    • Availability of Multidisciplinary Care Models Improves Patient Treatment Continuity
    • Expansion of Lung Transplant Programs Sustains Demand for Pre- and Post-Therapy Drugs
    • OEM-Driven Expansion of Global Clinical Trial Networks Supports Regulatory Approval in New Regions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pulmonary Fibrosis Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Monotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Symptomatic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Symptomatic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Familial PF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Familial PF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Familial PF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Mail Order Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Mail Order Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Mail Order Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Pulmonary Fibrosis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Pulmonary Fibrosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Pulmonary Fibrosis Treatment by Therapy Type - Monotherapy, Combination Therapy and Symptomatic Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Pulmonary Fibrosis Treatment by Therapy Type - Percentage Breakdown of Value Sales for Monotherapy, Combination Therapy and Symptomatic Treatment for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Pulmonary Fibrosis Treatment by Indication - Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Pulmonary Fibrosis Treatment by Indication - Percentage Breakdown of Value Sales for Idiopathic Pulmonary Fibrosis, Familial PF and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Pulmonary Fibrosis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Pulmonary Fibrosis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacy Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION